An economic analysis of interventions for diabetes

Diabetes Care

Volumn 23, Issue 3, 2000, Pages 390-404

  Klonoff, David C ^a,b   Schwartz, Daniel M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b FACP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL;

BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; COST BENEFIT ANALYSIS; COST CONTROL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; EXERCISE; HUMAN; LASER COAGULATION; QUALITY ADJUSTED LIFE YEAR; REVIEW; SCREENING; SMOKING CESSATION;

EID: 0034048782     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.23.3.390     Document Type: Review

References (97)

1. Detsky AS: Are clinical trials a cost-effective investment? JAMA 262:1795-1800, 1989
2. Mandelblatt JS, Fryback DG, Weinstein MC, Russell LB, Gold MR: Assessing the effectiveness of health interventions for cost-effectiveness analysis. Panel on Cost-Effectiveness in Health and Medicine. J Gen Intern Med 12:551-558, 1997
3. Vijan S, Stevens DL, Herman WH, Funnell MM, Standiford CJ: Screening, prevention, counseling, and treatment for the complications of type II diabetes mellitus: putting evidence into practice. J Gen Intern Med 12: 567-580, 1997
4. American Diabetes Association: Standards of medical care for patients with diabetes mellitus (Position Statement). Diabetes Care 21 (Suppl. 1):S5-S13, 1998
5. Diabetes Coalition of California: Basic guidelines for diabetes care. Medical Board of California Action Report 62:4-5, 1997
6. Karam JH: Diabetes mellitus and hypoglycemia. In Current Medical Diagnosis and Treatment 1997. 36th ed. Tierney LM Jr, McPhee SJ, Papadakis MA, Eds. Stamford, CT, Appleton and Lange, 1997, p. 1069-1109
7. Foster DW: Diabetes mellitus. In Harrison's Principles of Internal Medicine. 14th ed. Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, Eds. New York, McGraw-Hill, 1998, p. 2060-2081
8. Eisenberg JM: Clinical economics: a guide to the economic analysis of clinical practices. JAMA 262:2879-2886, 1989
9. Task Force on Principles for Economic Analysis of Health Care Technology: Economic analysis of health care technology: a report on principles. Ann Intern Med 122: 61-70, 1995
10. Siegel JE, Weinstein MC, Russell LB, Gold MR: Recommendations for reporting cost-effectiveness analyses. JAMA 276:1339-1341, 1996
11. Kaplan RM, Bush JW: Health-related quality of life measurement for evaluation research and policy analysis. Health Psychol 1:61-80, 1982
12. Laupecis A, Feeny D, Detsky AS, Tugwell PX: How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 146:473-481, 1992
13. Goldman L, Gordon DJ, Rifkind BM, Hulley SB, Detsky AS, DeWitt S, Kinosian B, Weinstein MC: Cost and health implications of cholesterol lowering. Circulation 85:1960-1968, 1992
14. U.S. Department of Labor: Consumer Price Index, All Urban Consumers, U.S. city average medical care. Washington, DC, U.S. Department of Labor, Bureau of Labor Statistics, 1998
15. Board of Governors of the Federal Reserve System: Federal Reserve Bulletin. Vol. 83, no. 1. Board of Governors of the Federal Reserve System, Washington, D.C., January 1997
16. Savolainen EA, Lee QP: Diabetic retinopathy: need and demand for photocoagulation and its cost-effectiveness: evaluation based on services in the United Kingdom. Diabetologia 23:138-140, 1982
17. Foulds WS, McCuish A, Barrie T, Green F, Scobie IN, Ghafour IM, McClure E, Barber JH: Diabetic retinopathy in the West of Scotland: its detection and prevalence, and the cost-effectiveness of a proposed screening programme. Health Bull 41:318-326, 1983
18. Javitt JC, Canner JK, Sommer A: Cost effectiveness of current approaches to the control of retinopathy in type I diabetics. Ophthalmology 96:255-264, 1989
19. Javilt JC, Canner JK, Frank RG, Steinwachs DM, Sommer A: Detecting and treating retinopathy in patients with type 1 diabetes mellitus: a health policy model. Ophthalmology 97:483-495, 1990
20. Dasbach EJ, Fryback DG, Newcomb PA, Klein R, Klein BEK: Cost-effectiveness of strategies for detecting diabetic retinopathy. Med Care 29:20-39, 1991
21. Javitt JC, Aiello L, Lloyd PA, Bassi LJ, Chiang YP, Canner JK: Detecting and treating retinopathy in patients with type I diabetes mellitus: savings associated with improved implementation of current guidelines. Ophthalmology 98:1565-1574, 1991
22. Fendrick AM, Javitt JC, Chiang YP: Cost-effectiveness of the screening and treatment of diabetic retinopathy: what are the costs of underutilization? Int J Technol Assess Health Care 8:694-707, 1992
23. Drummond MF, Davies LM, Ferris FL III: Assessing the costs and benefits of medical research: the diabetic retinopathy study. Soc Sci Med 34:973-981, 1992
24. Javitt JC, Aiello LP, Chiang YP, Ferris FL III, Canner JK, Greenfield S: Preventative eye care in people with diabetes is cost-saving to the federal government. Diabetes Care 17:909-917,1994
25. Matz H, Falk M, Gottinger W, Kieselbach G: Cost-benefit analysis of diabetic eye disease. Ophthalmologica 210:348-353, 1996
26. Fonseca V, Munshi M, Merin LM, Bradford JD: Diabetic retinopathy: a review for the primary care physician. South Med J 89: 839-850, 1996
27. Drummond MF: Economic aspects of cataract. Ophthalmology 95:1147-1153, 1988
28. Javitt JC, Aiello LP: Cost-effectiveness of detecting and treating diabetic retinopathy. Ann Intern Med 124:164-169, 1996
29. Hare JW: Diabetes and pregnancy. In Joslin's Diabetes Mellitus. 13th ed. Kahn CR, Weir GC, Eds. Philadelphia, Lea & Febiger, 1994, p. 889-899
30. Kitzmiller JL, Buchanan TA, Kjos S, Combs CA, Ranter RE: Preconception care of diabetes, congenital malformations, and spontaneous abortions (Technical Review). Diabetes Care 19:514-541, 1996
31. Scheffler RM, Feuchtbaum LB, Phibbs CS: Prevention: the cost-effectiveness of the California Diabetes and Pregnancy Program. Am J Public Health 82:168-175, 1992
32. Elixhauser A, Weschler JM, Kitzmiller JL, Marks JS, Bennert HW, Coustan DR, Gabbe SG, Herman WH, Kaufmann RC, Ogata ES, Sepe SJ: Cost-benefit analysis of preconception care for women with established diabetes mellitus. Diabetes Care 16: 1146-1157, 1993
33. Elixhauser A, Kitzmiller JL, Weschler JM: Short-term cost benefit of pre-conception care for diabetes (Letter). Diabetes Care 19: 384, 1996
34. Lewis EJ, Hunsicker LG, Bain RP, Rohde R: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
35. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M: Long-term stabilizing effect of angiotensin-converting enzyme inhibitor on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Int Med 118:577-581, 1993
36. Siegel JE, Krolewksi AS, Warram JH, Weinstein MC: Cost-effectiveness of screening and early treatment of nephropathy in patients with insulin-dependent diabetes mellitus. J Am Soc Nephrol 3:S111-S119, 1992
37. Borch-Johnsen K, Wenzel H, Viberti GC, Mogensen CE: Is screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes? BMJ 306:1722-1725, 1993
38. Kiberd BA, Jindal KK: Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation. BMJ 311: 1595-1599, 1995
39. Hendry BM, Viberti GC, Hummel S, Bagust A, Piercy J: Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type 1 diabetic patients. Q J Med 90:277-282, 1997
40. Garattini L, Brunetti M, Salvioni F, Barosi M: Economic evaluation of ACE inhibitor treatment of nephropathy in patients with insulin-dependent diabetes mellitus in Italy. Pharmacoeconomics 12:67-75, 1997
41. Rodby RA, Lewis EJ, Firth LM, The Collaborative Study Group: An economic analysis of captopril in the treatment of diabetic neuropathy. Diabetes Care 19: 1051-1061, 1966
42. LeFloch JP, Charles MA, Philippon C, Perlemuter L: Cost-effectiveness of screening for microalbuminuna using immunochemical dipstick tests or laboratory assays in diabetic patients. Diabet Med 11:349-356, 1994
43. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
44. The Diabetes Control and Complications Trial Research Group: Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial. JAMA 276:1409-1415, 1996
45. The Diabetes Control and Complications Trial Research Group: Resource utilization and costs of care in the Diabetes Control and Complications Trial. Diabetes Care 18: 1468-1478, 1995
46. Stern Z, Levy R: Analysis of direct cost of standard compared with intensive insulin treatment of insulin-dependent diabetes mellitus and cost of complications. Acta Diabetol 33:48-52, 1996
47. Stern Z, Levy R: The direct cost of type 1 diabetes mellitus in Israel. Diabet Med 11: 528-533, 1994
48. Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Copley-Merriman C, Maier W, Dong F, Manninen D, Zbrozek AS, Kotsanos J, Garfield SA, Harris M: Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 20:735-744, 1997
49. Law AV, Pathak DS, Segraves AM, Weinstein CR, Arneson WH: Cost-effectiveness analyses of the conversion of patients with non-insulin-dependent diabetes mellitus from glipizide to glyburide and of the accompanying pharmacy follow-up clinic. Clin Ther 17:977-987, 1995
50. Spaulding RH, Spaulding WB: The diabetic day-care unit. II. Comparison of patients and costs of initiating insulin therapy in the unit and a hospital. Can Med Assoc J 114: 780-783, 1976
51. Laugharne E, Steiner G: Tri-hospital Diabetes Education Center (Tridec): a cost effective, cooperative venture. Can Nurse 70:14-19, 1977
52. Davidson JK, Delcher HK, Englund A: Spinoff cost/benefits of expanded nutritional care. J Am Diet Assoc 75:250-257, 1979
53. Nersesian W, Zaremba M, Willhoite B: Impact of diabetes outpatient education program: Maine. MMWR 31:307-314, 1982
54. Schwartz R, Zaremba M, Ra K: Third-party coverage for diabetes education program. ORB 11:213-217, 1985
55. Zaremba MM, Willhoite B, Ra K: Self-reported data: reliability and role in determining program effectiveness. Diabetes Care 8:486-490, 1985
56. Whitehouse FW, Whitehouse IJ, Cox MS, Goldman J, Kahkonen DM. Partamian J, Tamayo RC: Outpatient regulation of the insulin-requiring person with diabetes (an alternative to hospitalization). J Chron Dis 36:433-438, 1983
57. Fishbein HA: Precipitants of hospitalization in insulin-dependent diabetes mellitus (IDDM): a statewide perspective. Diabetes Care 8:61-64, 1985
58. Rettig BA, Shrauger DG, Recker RR, GallagherTF, Wiltse H: The randomized study of the effects of a home diabetes education program. Diabetes Care 9:173-178, 1986
59. Bruce DG, Clark EM, Danesi GA, Campbell LV, Chisholm DJ: Outpatient initiation of insulin therapy in patients with diabetes mellitus. Med J Aust 146:19-22, 1987
60. de Weerdt I, Visser AP, Kok GJ, de Weerdt O, van der Veen EA: Randomized, controlled multicentre evaluation of an education programme for insulin-treated diabetic patients: effects on metabolic control, quality of life and costs of therapy. Diabet Med 8:338-345, 1991
61. Kaplan RM, Davis WK: Evaluating the costs and benefits of outpatient diabetes education and nutrition counseling. Diabetes Care 9:81-86, 1986
62. Feddersen E, Lockwood DH: An inpatient diabetes educator's impact on length of hospital stay. Diabetes Educ 20:125-128, 1994
63. Stuart ME: Redefining boundaries in the financing and care of diabetes: the Maryland experience. Milbank Q 72:679-694, 1994
64. Levetan CS, Salas JR, Wilets IF, Zumoff B: Impact of endocrine and diabetes team consultation on hospital length of stay for patients with diabetes. Am J Med 99:22-28, 1995
65. Edelstein EL, Cesta TG: Nursing case management: an innovative model of care for hospitalized patients with diabetes. Diabetes Educ 19:517-521, 1993
66. Drozda DJ, Dawson VA, Long DJ, Freson LS, Sperling MA: Assessment of the effect of a comprehensive diabetes management program on hospital admission rates of children with diabetes mellitus. Diabetes Educ 16:389-393, 1990
67. Aubert RE, Herman WH, Waters J, Moore W, Sutton D, Peterson BL, Bailey CM, Koplan JP: Nurse case management to improve glycemic control in diabetic patients in a health maintenance organization: a randomized, controlled trial. Ann Intern Med 129:605-612, 1998
68. Franz MJ, Splett PL, Monk A, Barry B, McLain K, Weaver T, Cooper N, Upham P, Bergenstal R, Mazze RS: Effectiveness of medical nutrition therapy provided by dietitians in the management of non-insulin-dependent diabetes mellitus: a randomized, controlled clinical trial. J Am Diet Assoc 95: 1009-1017, 1995
69. Monk A. Barry B, McClain K, Weaver T. Cooper N, Franz MJ: Practice guidelines for medical nutrition therapy provided by dietitians for persons with non-insulin-dependent diabetes mellitus. J Am Diet Assoc 95: 999-1006, 1995
70. Franz MJ. Splett PL, Monk A. Barry B, McLain K, Weaver T, Upham P, Bergenstal R, Mazze RS: Cost-effectiveness of medical nutrition therapy provided by dietitians for persons with non-insulin-dependent diabetes mellitus. J Am Diet Assoc 95:1018-1024, 1995
71. Starostina EG, Antsiferov M, Galstyan GR, Trautner C, Jorgens V, Bott U, Muhlhauser I, Berger M, Dedov II: Effectiveness and cost-benefit analysis of intensive treatment and teaching programmes for type 1 (insulin-dependent) diabetes mellitus in Moscow: blood glucose versus urine glucose self-monitoring. Diabetologia 37:170-176, 1994
72. Allen BT, DeLong ER, Feussner JR: Impact of glucose self-monitoring on non-insulin-treated patients with type II diabetes mellitus. Diabetes Care 13:1044-1050, 1990
73. Mackey WC, McCullough JL, Conlon TP, Shepard AD, Deterling RA, Callow AD, O'Donnell TF: The costs of surgery for limb-threatening ischemia. Surgery 99:27-35, 1986
74. Raviola CA, Nichter LS, Baker D, Busuttil RW; Machleder HI, Moore WS: Cost of treating advanced leg ischemia. Arch Surg 123:495-496, 1988
75. Gupta SK, Veith FJ, Ascer E, White Flores SA, Gliedman ML: Cost factors in limbthreatening ischaemia due to infrainguinal arteriosclerosis. Eur J Vasc Surg 2:151-154, 1988
76. Cheshire NJW, Wolfe JHN, Noone MA, Davies L, Drummond M: The economics of femorocrural reconstruction for critical leg ischemia with and without autologous vein. J Vasc Surg 15:167-175, 1992
77. Gibbons GW, Marcaccio EJ, Burgess AM, Pomposelli FB, Freeman DV, Campbell DR, Miller A, LoGerfo FW: Improved quality of diabetic foot care, 1984 vs 1990. Arch Surg 128:576-581, 1993
78. Panayiotopoulus YP, Tyrrell MR, Owen SE, Reidy JF, Taylor PR: Outcome and cost analysis after lemorocrural and femoropedal grafting for critical limb ischaemia. Br J Surg 84:207-212, 1997
79. Connell FA, Shaw C. Will J: Lower extremity amputations among persons with diabetes mellitus: Washington, 1988. MMWR 40:737-739, 1991
80. Bild DE, Selby JV, Sinnock P, Browner WS, Braveman P, Showstack JA: Lower-extremity amputation in people with diabetes: epidemiology and prevention. Diabetes Care 12:24-31, 1989
81. Litzelman DK, Slemenda CW, Langefeld CD, Hays LM, Welch MA, Bild DE, Ford ES, Vinicor F: Reduction of lower extremity clinical abnormalities in patients with non-insulin-dependent diabetes mellitus. Ann Intern Med 119:36-41, 1993
82. Litzelman DK, Marriott DJ, Vinicor F: Independent physiological predictors of foot lesions in patients with NIDDM. Diabetes Care 20:1273-1278, 1997
83. Jonsson B: Measurement of health outcome and associated costs in cardiovascular disease. Eur Heart J 17 (Suppl. A):2-7, 1996
84. Pharoah PDP, Hollingworth W: Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. BMJ 312:1443-1448, 1996
85. Marwick C: Intensive smoking cessation efforts cost-effective (Editorial). JAMA 276: 1291, 1996
86. Hatziandreau EI, Koplan JP, Weinstein MC, Caspersen CJ, Warner KE: A cost-effectiveness analysis of exercise as a health promotion activity. Am J Public Health 78:1417-1421, 1988
87. Bray GA: Health hazards of obesity. Endocrinol Metab Clin North Am 25:907-919, 1996
88. Goldstein DE, Little RR, Wiedmeyer HM, England JD, Rohlfing CL, Wilke AL: Is glycohemoglobin testing useful in diabetes mellitus? Lessons from the Diabetes Control and Complications Trial. Clin Chem 40: 1637-1640, 1994
89. Arden NH, Cox NJ, Schonbeger LB: Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR 45:1-24, 1996
90. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR: Pneumococcal polysaccharide vaccine efficacy. JAMA 270:1826-1831, 1993
91. U.K. Prospective Diabetes Study Group: Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes (UKPDS 40). BMJ 317:720-726, 1998
92. Torrance GW: Measurement of health status utilities for economic appraisal: a review. J Health Econ 5:1-30, 1986
93. Robinson R: Cost-utility analysis. BMJ 307: 859-862, 1993
94. Loomes G, McKenzie L: The use of QALYs in health care decision making. Soc Sci Med 28:299-308, 1989
95. Robinson R: Economic evaluation and health care: what does it mean? BMJ 307: 670-673, 1993
96. Krahn M, Gafni A: Discounting in the economic evaluation of health care interventions. Med Care 31:403-418, 1993
97. Ganiats TG: Discounting in cost-effectiveness research. Med Decis Making 14:298-300, 1994